Geostellar, a startup that coordinates the process for a solar photovoltaic system installation, rolled out an online marketplace in the Mid-Atlantic, New England and West Coast, including the San Francisco Bay Area. The platform gives people instant, free and independent appraisal of the value of the sunlight that shines on each and every roof. The company is partnering with Real Goods Solar, which has offices in Marin County. Geostellar's system uses a three-dimensional analysis to map sunlight to the square meter, allowing detailed of solar energy production.Law
The Farm-to-Consumer Legal Defense Fund has agreed to administer a litigation fund to be used to help finance Drakes Bay Oyster Company's lawsuit against the National Park Service. Drakes Bay Oyster Company is a family-owned, environmentally sustainable oyster farm on the shores of Drakes Estero within the confines of the Point Reyes National Seashore in Marin County, California. On Nov. 29, 2012, Secretary of the Interior Kenneth Lee Salazar issued his decision for the National Park Service not to renew a lease that the company had with the federal government and ordered the company off the land within 90 days. This would mean the job loss of 31 full-time employees and millions of dollars in oyster products. The company filed a lawsuit against NPS on December 4, 2012 in the United States District Court for the Northern District of California, seeking a declaration that the decision not to renew its lease was not in accordance with applicable law. The company has also filed for Motion for a Preliminary Injunction seeking to put a hold on the Park Service's decision while the lawsuit is ongoing.Construction
Ghilotti Bros., Inc. of San Rafael was recently recognized as award recipients in partnership with Caltrans and Liberty Mutual for the Lost Control Silver Safety Award for the Highway 101 widening project around Wilfred Avenue in Rohnert Park. This project was included in Caltrans pilot Rolling Owner Controlled Insurance Program program. To be included in the pilot ROCIP program, a project must be a highway construction project with a construction value of at least $25 million. Caltrans selected a number of projects throughout the state to participate in its pilot ROCIP. The purpose of this program is to evaluate and validate the following conditions including potential cost savings arise from the prevention of losses, reduction of the cost of those losses through consolidated claims management, reduction in cost of claims through a single insurer’s legal defense and reduction in premiums from the negotiating clout achieved by combining multiple insurance programs into one.Technology
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), signed a $50 million loan agreement with HealthCare Royalty Partners to help fund the commercialization of Procysbi, the branded name of RP103 for the potential treatment of nephropathic cystinosis, and advance the company's development programs. Under the terms of the agreement, Novato-based Raptor will receive $25 million at closing and an additional $25 million upon U.S. Food and Drug Administration approval of PROCYSBI. The First Tranche and Second Tranche Loans, which mature on Dec. 31, 2019, bear interest at an annual fixed rate of 10.75 percent and a Synthetic Royalty variable rate, tiered down, based on a percentage of future PROCYSBI sales. The loan is interest-only for the first two years.
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a Petaluma-based health care company that designs, produces and markets anti-infective products and medical devices and drug candidates, was issued a U.S. patent for the use of Microcyn technology in the treatment of skin ulcers. In this application, Microcyn Technology can be delivered to skin ulcers via washing, irrigation and soaking or through application of a wound dressing saturated in the Microcyn Technology. According to claims allowed by the patent examiner, the application of the Microcyn Technology via these methods will reduce the microbial load of an infected diabetic foot ulcer, decrease the recurrence rate of an infected diabetic foot ulcer, decrease the likelihood of amputation resulting from an infected diabetic foot ulcer and provide other benefits compared to current available treatments.